{"schema_version":"1","generated_at":"2026-11-03T09:48:06.857Z","data_as_of":null,"url":"https://www.findmykol.com/kol/aaron-ciner","json_url":"https://www.findmykol.com/kol/aaron-ciner/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"aaron-ciner","name":"Aaron Ciner","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"New Brunswick","state":"NJ","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1972917540","orcid":"0000-0002-5656-0758","openalex":"A5035270465"},"summary":"Aaron Ciner is an Oncology physician. OpenAlex indexes 35 publications with 212 citations (h-index 8); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":35,"cited_by_count":212,"h_index":8,"latest_activity_year":2026,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT04098081","title":"1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"University of Maryland, Baltimore","source_url":"https://clinicaltrials.gov/study/NCT04098081","trial_url":"https://www.findmykol.com/trial/NCT04098081"}],"source":"trials"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":1,"shown":1,"withheld":0,"rows":[{"payer":"ARRAY BIOPHARMA INC","program_year":2022,"amount_usd":21.62,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1972917540"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1972917540","source":"payments"},"prescribing":{"data_year":2024,"areas_total":6,"areas_shown":3,"areas":[{"area":"Nervous system","share_pct":37.1,"classes_total":3,"classes":[{"class":"Opioid Agonist","setting":"prescribed","share_pct":19.3,"drugs":[{"name":"Oxycodone Hcl","share_pct":100}],"max_beneficiaries":null},{"class":"Phenothiazine","setting":"prescribed","share_pct":11.4,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":17}]},{"area":"Metabolism & gastrointestinal","share_pct":26.7,"classes_total":2,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":20.8,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":26},{"class":"Opioid Agonist","setting":"prescribed","share_pct":5.9,"drugs":[{"name":"Loperamide","share_pct":100}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":10.9,"classes_total":2,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":5.4,"drugs":[{"name":"Imatinib Mesylate","share_pct":100}],"max_beneficiaries":null},{"class":"Leukocyte Growth Factor","setting":"prescribed","share_pct":5.4,"drugs":[{"name":"Zarxio","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":35,"shown":5,"withheld":30,"matched_by":"OpenAlex author record","recent":[{"title":"Dedifferentiated liposarcoma and 1,25 dihydroxyvitamin D-induced paraneoplastic hypercalcaemia","year":2026,"journal":"BMJ Case Reports","source_url":"https://doi.org/10.1136/bcr-2025-269928","status":"verified"},{"title":"Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma","year":2025,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-24-3149","status":"verified"},{"title":"Barriers and facilitators for participation in brain magnetic resonance imaging (MRI) scans in cancer research: a feasibility and acceptability analysis","year":2025,"journal":"Supportive Care in Cancer","source_url":"https://doi.org/10.1007/s00520-025-09549-9","status":"verified"},{"title":"The Interplay Between DNA Repair and the Immune Microenvironment in Pancreatic Cancer","year":2025,"journal":"Biomedicines","source_url":"https://doi.org/10.3390/biomedicines13051031","status":"verified"},{"title":"Protocols for Two Phase Ii Randomized Controlled Trials Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neurotoxicity (Cipn) and the Interoceptive Brain Circuitry in Patients with Breast or Gastrointestinal Cancers","year":2025,"journal":"SSRN Electronic Journal","source_url":"https://doi.org/10.2139/ssrn.5122547","status":"verified"}],"source":"works"},"contact":{"address_1":"195 LITTLE ALBANY ST","city":"New Brunswick","state":"NJ","zip":"089011914","phone":"732-828-3000","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1972917540","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":30}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2021-05-20","provider_certified":"2021-05-20","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}